On Tuesday, Alto Neuroscience, Inc. (NYSE:ANRO) revealed that the Phase 2b study of ALTO-100 for major depressive disorder (MDD) did not meet its primary endpoint compared to placebo. The ...
Palo Alto Networks PANW recently announced plans of its public offering of $1.75 billion aggregate principal amount of senior notes. The notes, slated for maturity in 2025, would be offered in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback